WO2005112919A8 - Self-immolative linkers and drug conjugates - Google Patents

Self-immolative linkers and drug conjugates

Info

Publication number
WO2005112919A8
WO2005112919A8 PCT/US2005/017804 US2005017804W WO2005112919A8 WO 2005112919 A8 WO2005112919 A8 WO 2005112919A8 US 2005017804 W US2005017804 W US 2005017804W WO 2005112919 A8 WO2005112919 A8 WO 2005112919A8
Authority
WO
WIPO (PCT)
Prior art keywords
self
drug
drug conjugates
immolative linkers
ligand
Prior art date
Application number
PCT/US2005/017804
Other languages
French (fr)
Other versions
WO2005112919A2 (en
WO2005112919A3 (en
Inventor
Sharon Boyd
Liang Chen
Sanjeev Gangwar
Vincent Guerlavais
Kilian Horgan
Zhi-Hong Li
Bilal Sufi
Original Assignee
Medarex Inc
Sharon Boyd
Liang Chen
Sanjeev Gangwar
Vincent Guerlavais
Kilian Horgan
Zhi-Hong Li
Bilal Sufi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ550934A priority Critical patent/NZ550934A/en
Priority to MXPA06013413A priority patent/MXPA06013413A/en
Priority to AU2005244980A priority patent/AU2005244980B2/en
Priority to JP2007527486A priority patent/JP4806680B2/en
Priority to BRPI0510909-4A priority patent/BRPI0510909A2/en
Priority to CA2564076A priority patent/CA2564076C/en
Priority to EP05752277.3A priority patent/EP1747021B1/en
Priority to CN200580020164.XA priority patent/CN1997402B/en
Application filed by Medarex Inc, Sharon Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Zhi-Hong Li, Bilal Sufi filed Critical Medarex Inc
Publication of WO2005112919A2 publication Critical patent/WO2005112919A2/en
Priority to IL179077A priority patent/IL179077A/en
Publication of WO2005112919A8 publication Critical patent/WO2005112919A8/en
Priority to KR1020067026578A priority patent/KR101079023B1/en
Priority to NO20065881A priority patent/NO20065881L/en
Publication of WO2005112919A3 publication Critical patent/WO2005112919A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Abstract

The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine or disulfide self-immolative linker. In a particular embodiment the cytotoxin is represented by duocarmycins and derivatives thereof. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
PCT/US2005/017804 2004-05-19 2005-05-19 Self-immolative linkers and drug conjugates WO2005112919A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP05752277.3A EP1747021B1 (en) 2004-05-19 2005-05-19 Self-immolative linkers and drug conjugates
AU2005244980A AU2005244980B2 (en) 2004-05-19 2005-05-19 Chemical linkers and conjugates thereof
JP2007527486A JP4806680B2 (en) 2004-05-19 2005-05-19 Self-sacrificing linker and drug conjugate
BRPI0510909-4A BRPI0510909A2 (en) 2004-05-19 2005-05-19 cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth
CA2564076A CA2564076C (en) 2004-05-19 2005-05-19 Chemical linkers and conjugates thereof
NZ550934A NZ550934A (en) 2004-05-19 2005-05-19 Chemical linkers and conjugates thereof
CN200580020164.XA CN1997402B (en) 2004-05-19 2005-05-19 Cytotoxic compounds and conjugates
MXPA06013413A MXPA06013413A (en) 2004-05-19 2005-05-19 Chemical linkers and conjugates thereof.
IL179077A IL179077A (en) 2004-05-19 2006-11-06 Chemical linkers and conjugates thereof
KR1020067026578A KR101079023B1 (en) 2004-05-19 2006-12-16 Chemical linkers and conjugates thereof
NO20065881A NO20065881L (en) 2004-05-19 2006-12-18 Chemical bonds and conjugates thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57266704P 2004-05-19 2004-05-19
US60/572,667 2004-05-19
US66117405P 2005-03-09 2005-03-09
US60/661,174 2005-03-09
US66987105P 2005-04-08 2005-04-08
US60/669,871 2005-04-08

Publications (3)

Publication Number Publication Date
WO2005112919A2 WO2005112919A2 (en) 2005-12-01
WO2005112919A8 true WO2005112919A8 (en) 2006-12-07
WO2005112919A3 WO2005112919A3 (en) 2007-02-01

Family

ID=35428830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017804 WO2005112919A2 (en) 2004-05-19 2005-05-19 Self-immolative linkers and drug conjugates

Country Status (12)

Country Link
US (1) US7517903B2 (en)
EP (1) EP1747021B1 (en)
JP (1) JP4806680B2 (en)
KR (1) KR101079023B1 (en)
AU (1) AU2005244980B2 (en)
BR (1) BRPI0510909A2 (en)
CA (1) CA2564076C (en)
IL (1) IL179077A (en)
MX (1) MXPA06013413A (en)
NO (1) NO20065881L (en)
NZ (1) NZ550934A (en)
WO (1) WO2005112919A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067930A1 (en) * 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CN101671335A (en) 2001-05-31 2010-03-17 梅达莱克斯公司 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CN101124249B (en) * 2005-02-18 2011-06-29 米德列斯公司 Human monoclonal antibodies to prostate specific membrane antigen(PSMA)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
AU2012227185B2 (en) * 2005-08-24 2015-07-02 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
NZ609752A (en) 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
ES2375843T3 (en) * 2005-10-26 2012-03-06 Medarex, Inc. PROCEDURES AND COMPOUNDS FOR THE PREPARATION OF ANC? LOGOS OF CC-1065.
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
PL1957539T3 (en) 2005-12-08 2013-08-30 Squibb & Sons Llc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
US20090175886A1 (en) 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
CA2641899A1 (en) 2006-02-02 2007-08-09 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
CN101627055A (en) 2006-09-05 2010-01-13 梅达雷克斯公司 The antibody of bone morphogenetic protein and acceptor thereof and their using method
CN101578287B (en) * 2006-09-06 2012-09-05 阿特纳赞塔里斯有限公司 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
JP5340155B2 (en) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Conjugates and derivatives of disorazole having cell-binding molecules, novel disorazole derivatives, their production and use
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
TWI412367B (en) * 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
EP2126127B1 (en) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
AR065404A1 (en) * 2007-02-21 2009-06-03 Medarex Inc PHARMACO-BINDING CONJUGATES, THOSE WHO JOIN POWERFUL CYTOTOXINS, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM AND THEIR USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER
AU2008227123B2 (en) * 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009017394A1 (en) * 2007-08-01 2009-02-05 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
US9901567B2 (en) * 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
HUE047200T2 (en) 2007-08-17 2020-04-28 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2009029727A1 (en) * 2007-08-28 2009-03-05 Vanderbilt University Cannabinoid receptor targeted agent
EP2195017B1 (en) * 2007-10-01 2014-10-22 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
AR069746A1 (en) * 2007-11-30 2010-02-17 Medarex Inc ANTI-RG-1 ANTIBODY CONJUGATES
EP2224958A2 (en) * 2007-11-30 2010-09-08 Bristol-Myers Squibb Company Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
KR20100101124A (en) * 2007-11-30 2010-09-16 브리스톨-마이어스 스큅 컴퍼니 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
BRPI0921687A8 (en) 2008-11-03 2022-11-08 Syntarga Bv COMPOUND, CONJUGATE, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A MAMMAL IN NEED THEREOF, AND, METHOD FOR TREATING OR PREVENTING A TUMOR IN A MAMMAL.
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
PT2403878T (en) 2009-03-05 2017-09-01 Squibb & Sons Llc Fully human antibodies specific to cadm1
LT2437790T (en) 2009-06-03 2019-06-10 Immunogen, Inc. Conjugation methods
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011089214A1 (en) * 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
ES2815678T3 (en) 2010-04-21 2021-03-30 Syntarga Bv Conjugates of CC-1065 Analogs and Bifunctional Linkers
DK3029066T3 (en) 2010-07-29 2019-05-20 Xencor Inc ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2621954A1 (en) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
KR20220009505A (en) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 Preparation of maytansinoid antibody conjugates by a one-step process
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
EP2836494B1 (en) * 2012-04-05 2019-08-21 Nerviano Medical Sciences S.r.l. New alkylating agents
ES2686683T3 (en) * 2012-04-05 2018-10-19 Nerviano Medical Sciences S.R.L. Functionalized thieno-indole derivatives
NZ724892A (en) 2012-05-15 2018-04-27 Seattle Genetics Inc Self-stabilizing linker conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6425650B2 (en) * 2012-06-07 2018-11-21 アンブルックス, インコーポレイテッドAmbrx, Inc. Prostate-specific membrane antigen antibody drug complex
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
IN2015DN03202A (en) 2012-10-04 2015-10-02 Immunogen Inc
KR20230142808A (en) 2012-10-11 2023-10-11 다이이찌 산쿄 가부시키가이샤 Method for producing a glycinamide compound
EA201590622A1 (en) 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION
ES2782248T3 (en) * 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
LT2956173T (en) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2906784C (en) 2013-03-15 2023-02-28 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
EA201690388A1 (en) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити NEW DERIVATIVES OF UNCIALAMICINE, METHODS OF THEIR SYNTHESIS AND THEIR APPLICATION AS ANTI-TUMOR AGENTS
ES2738657T3 (en) * 2013-09-25 2020-01-24 Nerviano Medical Sciences Srl Thieno [2,3-e] indole derivatives as new antitumor
EP3055331B1 (en) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
PE20160678A1 (en) 2013-10-18 2016-08-06 Deutsches Krebsforsch MARKED MEMBRANE-SPECIFIC PROSTATIC ANTIGEN INHIBITORS (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3082878B1 (en) 2013-12-19 2022-10-05 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
KR102535900B1 (en) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-trop2 antibody-drug conjugate
KR102384740B1 (en) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 Sulfonamide-containing linkage systems for drug conjugates
CN105899235B (en) 2014-01-10 2019-08-30 斯索恩生物制药有限公司 Method for purifying the antibody-drug conjugates of CYS connection
DK2948183T3 (en) 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv DUOCARMYCIN ADCS USED IN TREATMENT OF ENDOMETRY CANCER
LT3069735T (en) 2014-01-10 2018-06-11 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in the treatment of bladder cancer
WO2015110935A1 (en) 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
US10183970B2 (en) 2014-01-28 2019-01-22 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
SI3101032T1 (en) 2014-01-31 2019-02-28 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
AU2015231210B2 (en) 2014-03-20 2019-09-12 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
CR20160506A (en) 2014-03-28 2017-03-10 Xencor Inc Bispecific Antibodies that bind to CD38 and CD3
MY195180A (en) 2014-04-10 2023-01-11 U3 Pharma Gmbh Anti-HER3 Antibody-Drug Conjugate
WO2015155976A1 (en) * 2014-04-10 2015-10-15 第一三共株式会社 (anti-her2 antibody)-drug conjugate
JP6453706B2 (en) * 2014-05-23 2019-01-16 日本化薬株式会社 Novel glutamic acid derivatives and uses thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN117088931A (en) * 2014-08-12 2023-11-21 莫纳什大学 Prodrugs of directed lymphatics
US9879086B2 (en) 2014-09-17 2018-01-30 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3223845T3 (en) 2014-11-26 2021-08-16 Xencor Inc HETERODIMERING ANTIBODIES BINDING CD3 AND CD20
PT3233912T (en) 2014-12-19 2021-08-09 Regenesance B V Antibodies that bind human c6 and uses thereof
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
ES2747386T3 (en) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Heteroarylene-linked benzodiazepine dimers, conjugates thereof and methods of preparation and use
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2017002776A1 (en) 2015-06-29 2017-01-05 第一三共株式会社 Method for selectively manufacturing antibody-drug conjugate
JP7118888B2 (en) * 2015-09-08 2022-08-16 モナッシュ ユニバーシティ lymphotropic prodrug
WO2017053619A1 (en) 2015-09-23 2017-03-30 Bristrol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
JP6412906B2 (en) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Compound, linker-drug and ligand-drug complex
EA201891121A1 (en) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
CN108699136B (en) 2015-12-07 2022-03-18 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and PSMA
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
KR20180134351A (en) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. Process for the preparation of pegylated drug-linkers and intermediates thereof
JP2019515677A (en) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー Antibody conjugates and methods of making and using the same
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN116063545A (en) 2016-06-28 2023-05-05 Xencor股份有限公司 Heterodimeric antibodies that bind somatostatin receptor 2
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
EA201990470A1 (en) 2016-08-09 2019-09-30 Сиэтл Дженетикс, Инк. MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES
KR102493853B1 (en) 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3526241A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r heterodimeric fc-fusion proteins
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
KR20190095280A (en) 2016-12-12 2019-08-14 다이이찌 산쿄 가부시키가이샤 Combination of Antibody-Drug Conjugates and Immune Checkpoint Inhibitors
JP7244987B2 (en) 2016-12-14 2023-03-23 シージェン インコーポレイテッド Multidrug Antibody Drug Conjugates
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2019009117A (en) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof.
SG11201907050PA (en) 2017-02-28 2019-09-27 Univ Kinki Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
JP2020512312A (en) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド Process for the preparation of glucuronide drug-linker and its intermediates
CN110637036A (en) 2017-04-28 2019-12-31 味之素株式会社 Compound having affinity substance, cleavable moiety and reactive group for soluble protein, or salt thereof
CN110621337B (en) 2017-05-10 2021-11-09 浙江时迈药业有限公司 anti-LAG 3 human monoclonal antibodies and uses thereof
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
CN116333129A (en) 2017-05-25 2023-06-27 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions
CN111132733A (en) 2017-06-30 2020-05-08 Xencor股份有限公司 Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
JP7248578B2 (en) 2017-08-31 2023-03-29 第一三共株式会社 Novel methods for producing antibody-drug conjugates
EP3677589A4 (en) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11806407B2 (en) 2018-04-06 2023-11-07 University Of Notre Dame Du Lac Refillable drug delivery by affinity homing
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR20210010862A (en) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
EP4249002A3 (en) 2018-05-18 2023-11-22 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
CA3103151A1 (en) 2018-06-14 2019-12-19 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
JP7413999B2 (en) 2018-06-14 2024-01-16 味の素株式会社 Compounds having affinity for antibodies, cleavable moieties, and reactive groups, or salts thereof
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
TW202019473A (en) 2018-07-02 2020-06-01 美商安進公司 Anti-steap1 antigen-binding protein
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US20220072144A1 (en) 2018-09-20 2022-03-10 Daiichi Sankyo Company, Limited Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
JP2022503959A (en) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
CN113164780A (en) 2018-10-10 2021-07-23 泰洛斯治疗公司 anti-LAP antibody variants and uses thereof
GB201817321D0 (en) 2018-10-24 2018-12-05 Nanna Therapeutics Ltd Microbeads for tagless encoded chemical library screening
WO2020090979A1 (en) 2018-10-31 2020-05-07 味の素株式会社 Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020117627A1 (en) 2018-12-03 2020-06-11 Bristol-Myers Squibb Company Anti-ido antibody and uses thereof
CN109762067B (en) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
CN113396162A (en) 2019-01-22 2021-09-14 百时美施贵宝公司 Antibodies against IL-7R alpha subunit and uses thereof
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
US20220362397A1 (en) 2019-09-26 2022-11-17 Nof Corporation Heterobifunctional monodispersed polyethylene glycol having peptide linker
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
CN114945409A (en) 2020-01-13 2022-08-26 新免疫技术有限公司 Methods of treating tumors with combinations of IL-7 proteins and bispecific antibodies
US20230105029A1 (en) 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
BR112022020332A2 (en) 2020-04-10 2022-12-13 Seagen Inc ANTIBODY-DRUG CONJUGATE COMPOUND, COMPOSITION, METHOD OF TREATMENT OF CANCER AND AN AUTOIMMUNE DISORDER
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4163294A1 (en) 2020-06-09 2023-04-12 Ajinomoto Co., Inc. Modified ferritin and method for producing same
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN114685669A (en) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 Antibodies that bind TROP2 and uses thereof
CN117157319A (en) 2021-03-09 2023-12-01 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022248835A1 (en) 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
CA3234692A1 (en) 2021-09-30 2023-04-06 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0271581B1 (en) * 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US4994578A (en) * 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
US5147786A (en) * 1988-04-22 1992-09-15 Monsanto Company Immunoassay for the detection of α-haloacetamides
JP2642165B2 (en) * 1988-07-22 1997-08-20 協和醗酵工業株式会社 Novel DC-89 compound and method for producing the same
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (en) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 New substance DC113
JP2510335B2 (en) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 DC-88A derivative
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5334528A (en) * 1989-10-30 1994-08-02 The Regents Of The University Of California Monoclonal antibodies to cyclodiene insecticides and method for detecting the same
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0527189A1 (en) * 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69121334T2 (en) * 1990-07-26 1997-03-20 Kyowa Hakko Kogyo Kk DC-89 derivatives as anti-tumor agents
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (en) * 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
ATE463573T1 (en) * 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DK0563475T3 (en) * 1992-03-25 2000-09-18 Immunogen Inc Conjugates of Cell Binding Agents and Derivatives of CC-1065
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JP3514490B2 (en) * 1992-08-21 2004-03-31 杏林製薬株式会社 Trifluoromethylpyrroloindole carboxylate derivative and method for producing the same
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) * 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
DE4314091A1 (en) * 1993-04-29 1994-11-03 Boehringer Mannheim Gmbh Immunological detection method for triazines
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5786377A (en) * 1993-11-19 1998-07-28 Universidad De Santiago De Compostela Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications
CA2165819C (en) * 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
JPH07309761A (en) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd Method for stabilizing duocamycin derivative
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JP4157600B2 (en) * 1994-08-19 2008-10-01 ラ レフィオン バロンネ COMPOUND, COMPOSITION FOR PREPARATION, DIAGNOSTIC DEVICE CONTAINING THEM, AND USE THEREOF
CN1051552C (en) * 1994-11-29 2000-04-19 杏林制药株式会社 Acrylamide derivatives and process for producing the same
WO1996035451A1 (en) * 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Novel toxin complex
US5686237A (en) * 1995-06-05 1997-11-11 Al-Bayati; Mohammed A. S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997012862A1 (en) * 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
CA2187969C (en) * 1995-10-17 2006-05-30 Dale L. Boger A template for solution phase synthesis of combinatorial libraries
ES2195036T3 (en) * 1995-12-22 2003-12-01 Bristol Myers Squibb Co RAMIFIED HYDRAZONE CONNECTORS.
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
ES2244991T3 (en) * 1996-03-08 2005-12-16 The Scripps Research Institute ANALOGOSMCBI OF CC-1065 AND THE DUOCARMYCINS.
CA2255703A1 (en) * 1996-05-31 1997-12-04 Dale L. Boger Analogs of cc-1065 and the duocarmycins
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JPH1087666A (en) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd Intermediate for producing duocarmycin sa and its derivative and production thereof
WO1998043663A1 (en) 1997-03-28 1998-10-08 The Scripps Research Institute Sandramycin analogs
AU7274898A (en) * 1997-05-07 1998-11-27 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
CA2290789A1 (en) * 1997-05-22 1998-11-26 Dale L. Boger Analogs of duocarmycin and cc-1065
WO1999019298A1 (en) * 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
AU1807999A (en) * 1997-12-08 1999-06-28 Scripps Research Institute, The Synthesis of cc-1065/duocarmycin analogs
JP3045706B1 (en) * 1998-09-14 2000-05-29 科学技術振興事業団 Compound for alkylating a specific base sequence of DNA and method for synthesizing the same
ATE362940T1 (en) * 2000-03-16 2007-06-15 Genesoft Inc CHARGED COMPOUNDS WITH A NUCLEIC ACID BINDING UNIT AND THEIR USES
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CN101671335A (en) * 2001-05-31 2010-03-17 梅达莱克斯公司 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
JP2005511627A (en) * 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド Treatment of immunological diseases using anti-CD30 antibodies
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US20050180972A1 (en) * 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
ES2361739T3 (en) * 2002-08-16 2011-06-21 Immunogen, Inc. RETICULANTS WITH HIGH REACTIVITY AND SOLUBILITY AND ITS USE IN THE PREPARATION OF CONJUGATES FOR THE DIRECTED SUPPLY OF DRUGS OF SMALL MOLECULE.
ES2347959T3 (en) * 2003-02-20 2010-11-26 Seattle Genetics, Inc. ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof

Also Published As

Publication number Publication date
IL179077A (en) 2011-10-31
WO2005112919A2 (en) 2005-12-01
AU2005244980B2 (en) 2011-09-15
JP4806680B2 (en) 2011-11-02
CA2564076A1 (en) 2005-12-01
JP2007538099A (en) 2007-12-27
BRPI0510909A2 (en) 2008-12-16
CA2564076C (en) 2014-02-18
KR101079023B1 (en) 2011-11-01
AU2005244980A1 (en) 2005-12-01
NO20065881L (en) 2007-02-13
US20060004081A1 (en) 2006-01-05
US7517903B2 (en) 2009-04-14
IL179077A0 (en) 2008-03-20
MXPA06013413A (en) 2007-01-23
WO2005112919A3 (en) 2007-02-01
NZ550934A (en) 2010-05-28
KR20070048138A (en) 2007-05-08
EP1747021A2 (en) 2007-01-31
EP1747021B1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
WO2005112919A3 (en) Self-immolative linkers and drug conjugates
WO2007038658A3 (en) Antibody-drug conjugates and methods of use
WO2007059404A3 (en) Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007022493A3 (en) Ligand conjugates of vinca alkaloids, analogs, and derivatives
IL189461A (en) Process for preparing cell-binding agent-cytotoxic agent conjugates
WO2007011968A3 (en) Beta-glucuronide-linker drug conjugates
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
AU2003224644A1 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
MXPA03011094A (en) Cytotoxins, prodrugs, linkers and stabilizers useful therefor.
UA103758C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2009016516A3 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2005117986A3 (en) Antibody drug conjugates and methods
IL179633A0 (en) Drug compositions, fusions and conjugates
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
PL374523A1 (en) Calicheamicin derivative-carrier conjugates
WO2005116255A3 (en) Aptamer-toxin molecules and method for using same
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
UA95959C2 (en) Leptomycin derivatives
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2007005941A3 (en) Liver targeted conjugates
WO2007106544A3 (en) Chelating conjugates having a substituted aromatic moiety and derivatives thereof
WO2003045319A3 (en) Targeted therapeutics and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2564076

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005244980

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 550934

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 179077

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005752277

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200609483

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013413

Country of ref document: MX

Ref document number: 12006502301

Country of ref document: PH

Ref document number: 2007527486

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005244980

Country of ref document: AU

Date of ref document: 20050519

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005244980

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3745/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067026578

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580020164.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006144958

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005752277

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0510909

Country of ref document: BR